Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

First Report of Entrectinib as a Treatment Option for Pure Squamous Cell Carcinoma Harboring ROS1 Rearrangement: Exploring the Role of Next-Generation Sequencing in Targeted Therapy

International Journal of Molecular Sciences(2025)10.3390/ijms27010025Source: DataRank Database

First Report of Entrectinib as a Treatment Option for Pure Squamous Cell Carcinoma Harboring ROS1 Rearrangement: Exploring the Role of Next-Generation Sequencing in Targeted Therapy is a research paper published in International Journal of Molecular Sciences (2025). On theSindex it has a DataRank of 0.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access0 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (9 grants)Impact (FWCI 0.00)OA: goldTopics (29)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (4)

Rung-Hsuan Chen,Yung-Shin Lu,Chiao-En Wu ORCID,Yan-Jei Tang ORCID

Live enrichment

PubMed:41515905 PMC:PMC12785662 OpenAlex:https://openalex.org/W7116100273

Chang-Gung Memorial Hospital

Grant: CMRPG3J0971~3

Chang-Gung Memorial Hospital

Grant: CMRPVVP0111

Chang-Gung Memorial Hospital

Grant: CORPVVQ0021

Chang-Gung Memorial Hospital

Grant: CMRPVVQ0041

Chang-Gung Memorial Hospital

Grant: CMRPG3P0101

National Science and Technology Council

Grant: 113-2628-B-182-001-MY3

National Science and Technology Council

Grant: 113-2811-B-182-024

Chang-Gung Memorial Hospital

Grant: CMRPG3J0971~3, CMRPVVP0111, CORPVVQ0021, and CMRPVVQ0041 to CEW; CMRPG3P0101 to HJS

National Science and Technology Council

Grant: 113-2628-B-182-001-MY3 and 113-2811-B-182-024 to CEW

FWCI

0.00

Citation Percentile

0.6%

goldLicense: cc-by

journalhttps://www.mdpi.com/1422-0067/27/1/25/pdf?version=1766150068

publisherhttps://www.mdpi.com/1422-0067/27/1/25/pdf?version=1766150068

publisherhttps://www.mdpi.com/1422-0067/27/1/25/pdf

journalhttps://doi.org/10.3390/ijms27010025

repositoryhttps://pubmed.ncbi.nlm.nih.gov/41515905

Fields of Study

Lung Cancer Treatments and MutationsLung Cancer Research StudiesAcute Lymphoblastic Leukemia research

MeSH Terms

BenzamidesCarcinoma, Squamous CellFemaleHumansIndazolesLung NeoplasmsMaleMiddle AgedProtein-Tyrosine KinasesProto-Oncogene ProteinsGene RearrangementMolecular Targeted TherapyHigh-Throughput Nucleotide Sequencing

Keywords

ROS1Targeted therapyLung cancerPrecision medicinePersonalized medicineCancerDeep sequencingNon-small cell lung cancerNext-generation SequencingSquamous Cell Lung CancerNon-smokingRos1 RearrangementEntrectinib

Sustainable Development Goals

SDG 0: Good health and well-being